搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Shewanella oneidensis Glycine--tRNA ligase alpha subunit (glyQ) CSB-YP816398SGA
CSB-EP816398SGA
CSB-BP816398SGA
CSB-MP816398SGA
CSB-EP816398SGA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis Ribonuclease P protein component (rnpA) CSB-YP816399OAB
CSB-EP816399OAB
CSB-BP816399OAB
CSB-MP816399OAB
CSB-EP816399OAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis 50S ribosomal protein L9 (rplI) CSB-YP816400OAB
CSB-EP816400OAB
CSB-BP816400OAB
CSB-MP816400OAB
CSB-EP816400OAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis UPF0317 protein OB3382 (OB3382) CSB-YP816401OAB
CSB-EP816401OAB
CSB-BP816401OAB
CSB-MP816401OAB
CSB-EP816401OAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis Fructose-bisphosphate aldolase class 1 (fda) CSB-YP816402OAB
CSB-EP816402OAB
CSB-BP816402OAB
CSB-MP816402OAB
CSB-EP816402OAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis Xylose isomerase (xylA) CSB-YP816403OAB
CSB-EP816403OAB
CSB-BP816403OAB
CSB-MP816403OAB
CSB-EP816403OAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis ATP synthase subunit b (atpF), partial CSB-YP816404OAB1
CSB-EP816404OAB1
CSB-BP816404OAB1
CSB-MP816404OAB1
CSB-EP816404OAB1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis Probable 5-dehydro-4-deoxyglucarate dehydratase (OB2841) CSB-YP816405OAB
CSB-EP816405OAB
CSB-BP816405OAB
CSB-MP816405OAB
CSB-EP816405OAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis Ribose-5-phosphate isomerase A 2 (rpiA2) CSB-YP816406OAB
CSB-EP816406OAB
CSB-BP816406OAB
CSB-MP816406OAB
CSB-EP816406OAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis Ketol-acid reductoisomerase (ilvC) CSB-YP816407OAB
CSB-EP816407OAB
CSB-BP816407OAB
CSB-MP816407OAB
CSB-EP816407OAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis Ribose import ATP-binding protein RbsA (rbsA) CSB-YP816408OAB
CSB-EP816408OAB
CSB-BP816408OAB
CSB-MP816408OAB
CSB-EP816408OAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis UvrABC system protein A (uvrA), partial CSB-YP816409OAB
CSB-EP816409OAB
CSB-BP816409OAB
CSB-MP816409OAB
CSB-EP816409OAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis Enolase (eno) CSB-YP816410OAB
CSB-EP816410OAB
CSB-BP816410OAB
CSB-MP816410OAB
CSB-EP816410OAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis UPF0421 protein OB2406 (OB2406), partial CSB-YP816411OAB1
CSB-EP816411OAB1
CSB-BP816411OAB1
CSB-MP816411OAB1
CSB-EP816411OAB1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis Phosphoenolpyruvate carboxykinase [ATP] (pckA), partial CSB-YP816412OAB
CSB-EP816412OAB
CSB-BP816412OAB
CSB-MP816412OAB
CSB-EP816412OAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis Probable non-canonical purine NTP phosphatase (OB2237) CSB-YP816413OAB
CSB-EP816413OAB
CSB-BP816413OAB
CSB-MP816413OAB
CSB-EP816413OAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis UPF0173 metal-dependent hydrolase OB2186 (OB2186) CSB-YP816414OAB
CSB-EP816414OAB
CSB-BP816414OAB
CSB-MP816414OAB
CSB-EP816414OAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis Threonine--tRNA ligase (thrS), partial CSB-YP816415OAB
CSB-EP816415OAB
CSB-BP816415OAB
CSB-MP816415OAB
CSB-EP816415OAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis Cell division protein ZapA (zapA) CSB-YP816416OAB
CSB-EP816416OAB
CSB-BP816416OAB
CSB-MP816416OAB
CSB-EP816416OAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oceanobacillus iheyensis Probable GTP-binding protein EngB (engB) CSB-YP816417OAB
CSB-EP816417OAB
CSB-BP816417OAB
CSB-MP816417OAB
CSB-EP816417OAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見(jiàn)問(wèn)題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>